Twinbeech Capital LP Makes New $3.68 Million Investment in ADMA Biologics, Inc. (NASDAQ:ADMA)

Twinbeech Capital LP bought a new position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 214,710 shares of the biotechnology company's stock, valued at approximately $3,682,000. Twinbeech Capital LP owned about 0.09% of ADMA Biologics as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Tang Capital Management LLC purchased a new stake in ADMA Biologics during the fourth quarter worth $9,432,000. Sherbrooke Park Advisers LLC raised its position in shares of ADMA Biologics by 43.9% in the fourth quarter. Sherbrooke Park Advisers LLC now owns 20,066 shares of the biotechnology company's stock worth $344,000 after acquiring an additional 6,117 shares during the period. Rafferty Asset Management LLC boosted its stake in shares of ADMA Biologics by 31.2% during the 4th quarter. Rafferty Asset Management LLC now owns 513,128 shares of the biotechnology company's stock worth $8,800,000 after acquiring an additional 122,173 shares in the last quarter. Point72 Asset Management L.P. grew its position in shares of ADMA Biologics by 91.3% during the 4th quarter. Point72 Asset Management L.P. now owns 212,326 shares of the biotechnology company's stock valued at $3,641,000 after acquiring an additional 101,315 shares during the period. Finally, ProShare Advisors LLC grew its position in shares of ADMA Biologics by 30.2% during the 4th quarter. ProShare Advisors LLC now owns 79,286 shares of the biotechnology company's stock valued at $1,360,000 after acquiring an additional 18,375 shares during the period. Institutional investors and hedge funds own 75.68% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Raymond James increased their price target on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research report on Thursday, May 8th. Wall Street Zen downgraded ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $24.25.

Insider Activity at ADMA Biologics

In related news, Director Lawrence P. Guiheen sold 7,779 shares of the company's stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $20.32, for a total transaction of $158,069.28. Following the completion of the sale, the director now owns 114,830 shares of the company's stock, valued at approximately $2,333,345.60. This represents a 6.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 3.50% of the stock is owned by corporate insiders.

ADMA Biologics Price Performance

Shares of ADMA traded up $0.26 during mid-day trading on Friday, hitting $20.42. 1,316,575 shares of the company were exchanged, compared to its average volume of 3,696,807. The stock has a market cap of $4.87 billion, a price-to-earnings ratio of 72.93 and a beta of 0.57. ADMA Biologics, Inc. has a 1-year low of $9.35 and a 1-year high of $25.67. The company has a 50 day moving average of $20.64 and a 200-day moving average of $18.91. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). The firm had revenue of $114.80 million for the quarter, compared to analysts' expectations of $116.40 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. ADMA Biologics's quarterly revenue was up 40.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.08 earnings per share. Analysts expect that ADMA Biologics, Inc. will post 0.51 EPS for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.